Teva Pharmaceutical Industries Limited ( NYSE: TEVA) Barclays 27th Annual Global Healthcare Conference March 11, 2025 8:00 AM ET Good morning, everyone. My name is Balaji Prasad. I'm the Senior ...

Innovation, collaboration, and regulatory reform were on the agenda at the 2025 Clinical Trial Supply Europe conference.

The Federal Circuit’s refusal to reconsider its ruling forcing Teva to delist asthma-inhaler patents from the FDA’s Orange ...

Teva's business is encountering headwinds, including declining U.S. generics revenue. Read what this biotech plans to do in ...

A detailed review of a 6-month clinical trial further reinforces strong experimental evidence that a ketogenic diet may offer ...

The global orphan drug market size was USD 154.20 Billion in 2022 and is expected to register a rapid revenue CAGR of 12.3 % ...

Teva Pharmaceuticals filed a patent infringement lawsuit against Amneal Pharmaceuticals alleging that their generic version of ...

The drugs are listed in alphabetical order. Aprepitant oral suspension: Merck reported a shortage of Emend, its aprepitant oral suspension. Merck did not provide a reason for the shortage. The ...

The Europe Antibiotics Market is witnessing steady growth, driven by the increasing prevalence of infectious diseases, an aging population, and advancements in diagnostic capabilities. These factors ...

The severity of a patient’s chronic spontaneous urticaria impacted several outcomes, including quality of life and treatment ...

In this report the analyst provides an in-depth analysis of the key themes, strategic moves, and market dynamics presented at the conference, offering insights into how major players are positioning ...